These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 19891505)

  • 21. A putative bioactive conformation for the altered peptide ligand of myelin basic protein and inhibitor of experimental autoimmune encephalomyelitis [Arg91, Ala96] MBP87-99.
    Mantzourani ED; Tselios TV; Grdadolnik SG; Brancale A; Platts JA; Matsoukas JM; Mavromoustakos TM
    J Mol Graph Model; 2006 Sep; 25(1):17-29. PubMed ID: 16310386
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The myelin-associated oligodendrocytic basic protein (MOBP) as a relevant primary target autoantigen in multiple sclerosis.
    Kaushansky N; Eisenstein M; Zilkha-Falb R; Ben-Nun A
    Autoimmun Rev; 2010 Feb; 9(4):233-6. PubMed ID: 19683076
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical relevance of antibodies against myelin oligodendrocyte glycoprotein in different clinical types of multiple sclerosis.
    Zadro I; Brinar V; Horvat G; Brinar M
    Clin Neurol Neurosurg; 2007 Jan; 109(1):23-6. PubMed ID: 16750597
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiple sclerosis candidate autoantigens except myelin oligodendrocyte glycoprotein are transcribed in human thymus.
    Bruno R; Sabater L; Sospedra M; Ferrer-Francesch X; Escudero D; Martínez-Cáceres E; Pujol-Borrell R
    Eur J Immunol; 2002 Oct; 32(10):2737-47. PubMed ID: 12355425
    [TBL] [Abstract][Full Text] [Related]  

  • 25. IgG subclass switching is associated with the severity of experimental autoimmune encephalomyelitis induced with myelin oligodendrocyte glycoprotein peptide in NOD mice.
    Ichikawa M; Koh CS; Inaba Y; Seki C; Inoue A; Itoh M; Ishihara Y; Bernard CC; Komiyama A
    Cell Immunol; 1999 Feb; 191(2):97-104. PubMed ID: 9973531
    [TBL] [Abstract][Full Text] [Related]  

  • 26. NMR structural elucidation of myelin basic protein epitope 83-99 implicated in multiple sclerosis.
    Spyranti Z; Tselios T; Deraos G; Matsoukas J; Spyroulias GA
    Amino Acids; 2010 Mar; 38(3):929-36. PubMed ID: 19468823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Delineation of the minimal encephalitogenic epitope within the immunodominant region of myelin oligodendrocyte glycoprotein: diverse V beta gene usage by T cells recognizing the core epitope encephalitogenic for T cell receptor V beta b and T cell receptor V beta a H-2b mice.
    Mendel Kerlero de Rosbo N; Ben-Nun A
    Eur J Immunol; 1996 Oct; 26(10):2470-9. PubMed ID: 8898962
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Imperative role of glycosylation in human MOG-HLA interaction: molecular insights of MOG-Ab associated demyelination.
    Jayananth P; Madhumitha R; Ramya L
    J Biomol Struct Dyn; 2022 Sep; 40(15):7027-7037. PubMed ID: 33663341
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Conformational landscape of N-glycosylated peptides detecting autoantibodies in multiple sclerosis, revealed by Hamiltonian replica exchange.
    Guardiani C; Signorini GF; Livi R; Papini AM; Procacci P
    J Phys Chem B; 2012 May; 116(18):5458-67. PubMed ID: 22519978
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The glycan role in the glycopeptide immunogenicity revealed by atomistic simulations and spectroscopic experiments on the multiple sclerosis biomarker CSF114(Glc).
    Bruno A; Scrima M; Novellino E; D'Errico G; D'Ursi AM; Limongelli V
    Sci Rep; 2015 Mar; 5():9200. PubMed ID: 25776265
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Viability of autoantibody-targets: how to tackle pathogenetic heterogeneity as an obstacle for treatment of multiple sclerosis.
    Mayer MC; Hohlfeld R; Meinl E
    J Neurol Sci; 2012 Aug; 319(1-2):2-7. PubMed ID: 22647585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Computational methods and theory for ion channel research.
    Guardiani C; Cecconi F; Chiodo L; Cottone G; Malgaretti P; Maragliano L; Barabash ML; Camisasca G; Ceccarelli M; Corry B; Roth R; Giacomello A; Roux B
    Adv Phys X; 2022; 7(1):. PubMed ID: 35874965
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multiple replica repulsion technique for efficient conformational sampling of biological systems.
    Malevanets A; Wodak SJ
    Biophys J; 2011 Aug; 101(4):951-60. PubMed ID: 21843487
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Predominance of the autoimmune response to myelin oligodendrocyte glycoprotein (MOG) in multiple sclerosis: reactivity to the extracellular domain of MOG is directed against three main regions.
    Kerlero de Rosbo N; Hoffman M; Mendel I; Yust I; Kaye J; Bakimer R; Flechter S; Abramsky O; Milo R; Karni A; Ben-Nun A
    Eur J Immunol; 1997 Nov; 27(11):3059-69. PubMed ID: 9394837
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Experimental autoimmune encephalomyelitis induced with a combination of myelin basic protein and myelin oligodendrocyte glycoprotein is ameliorated by administration of a single myelin basic protein peptide.
    Leadbetter EA; Bourque CR; Devaux B; Olson CD; Sunshine GH; Hirani S; Wallner BP; Smilek DE; Happ MP
    J Immunol; 1998 Jul; 161(1):504-12. PubMed ID: 9647262
    [TBL] [Abstract][Full Text] [Related]  

  • 36. T-cell responses to myelin antigens in multiple sclerosis; relevance of the predominant autoimmune reactivity to myelin oligodendrocyte glycoprotein.
    de Rosbo NK; Ben-Nun A
    J Autoimmun; 1998 Aug; 11(4):287-99. PubMed ID: 9776706
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Fragment 101-108 of myelin oligodendrocyte glycoprotein: a possible lead compound for multiple sclerosis.
    Guardiani C; Marsili S; Procacci P; Livi R
    J Am Chem Soc; 2009 Dec; 131(47):17176-84. PubMed ID: 19891505
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Conformational structure of the MOG-derived peptide 101-108 in solution.
    Guardiani C; Marsili S; Marchetti S; Gambi C; Procacci P; Livi R
    Biopolymers; 2011; 96(3):245-51. PubMed ID: 20549678
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.